Cargando…

Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China

BACKGROUND: Brain metastasis (BM) frequently occurs in HER2-positive breast cancer (BC) patients, but the risk factors of BM in this type of patients are still unknown. Our study aims to assess the risk factors of BM and prognostic analysis in HER2-positive BC patients. METHODS: Univariate analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Shuang-Long, Wang, Zhi-Hong, Chen, Xiao-Geng, Han, Lei, Gong, Guo-Xian, Chen, Yan-Ping, Lin, Xiu-Quan, Ma, Tao, Chen, Hong-Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271963/ https://www.ncbi.nlm.nih.gov/pubmed/35832552 http://dx.doi.org/10.3389/fonc.2022.905065

Ejemplares similares

Erratum: Risk factors of brain metastasis and prognosis in HER2-positive breast cancer: A single-institution retrospective analysis from China
Publicado: (2022)

Risk factors of non-sentinel lymph node metastasis in 443 breast cancer patients with sentinel lymph node-positive
por: Cai, Shuang-long, et al.
Publicado: (2022)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
por: Zhao, Hengqiang, et al.
Publicado: (2021)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
por: Xu, Hangcheng, et al.
Publicado: (2022)

Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer
por: Cai, Shuang-Long, et al.
Publicado: (2023)

HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study
por: Shi, Jiajie, et al.
Publicado: (2023)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

Tryptophan Metabolites as Biomarkers for Esophageal Cancer Susceptibility, Metastasis, and Prognosis
por: Chen, Yun, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
por: Pellas, Ulrika, et al.
Publicado: (2023)

Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis
por: Mao, Xiaoyun, et al.
Publicado: (2022)

Subphrenic Lymph Node Metastasis Predicts Poorer Prognosis for Nasopharyngeal Carcinoma Patients With Metachronous Metastasis
por: Zhang, Xue-Fang, et al.
Publicado: (2021)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study
por: Liu, Chang-Gen, et al.
Publicado: (2023)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis, immune infiltration and chemotherapy resistance
por: Jin, RuiRi, et al.
Publicado: (2023)

Tumor Burden Score Stratifies Prognosis of Patients With Intrahepatic Cholangiocarcinoma After Hepatic Resection: A Retrospective, Multi-Institutional Study
por: Li, Hui, et al.
Publicado: (2022)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
por: Sun, Guang-Yi, et al.
Publicado: (2021)

CT characteristics for predicting prognosis of gastric cancer with synchronous peritoneal metastasis
por: Li, Jiazheng, et al.
Publicado: (2023)

Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World
por: Yu, Xingfei, et al.
Publicado: (2021)

An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer
por: Zhou, Jinmei, et al.
Publicado: (2022)

Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
por: Song, Zhengbo, et al.
Publicado: (2021)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
por: Deng, Ting, et al.
Publicado: (2023)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification
por: Meedendorp, Arenda D., et al.
Publicado: (2018)

Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
por: Yang, Zi-yan, et al.
Publicado: (2020)

Retrospective analysis of risk factors for distant metastasis of early-onset gastric cancer during the perioperative period
por: Bi, Bo, et al.
Publicado: (2023)

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab
por: Li, Fanfan, et al.
Publicado: (2022)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma
por: Chen, Nan, et al.
Publicado: (2023)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
por: Ma, Xiaoping, et al.
Publicado: (2022)

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
por: Chen, Min-long, et al.
Publicado: (2023)

The Clinicopathological Features and Prognosis in Patients With Papillary Renal Cell Carcinoma: A Multicenter Retrospective Study in Chinese Population
por: Hong, Baoan, et al.
Publicado: (2021)

The Therapeutic Challenge of Disseminated Bone Marrow Metastasis From HR-Positive HER2-Negative Breast Cancer: Case Report and Review of the Literature
por: Garufi, Giovanna, et al.
Publicado: (2021)

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
por: Di Cosimo, Serena, et al.
Publicado: (2023)

The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells
por: Sun, Li-Fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lbkldce84ur275lctn921o5i9f